Clearside Biomedical Secures Canadian Approval for XIPERE as Suprachoroidal Treatment for Uveitic Macular Edema

July 23, 2025

DENVER, Colo., Jul 23, 2025 (247marketnews.com)- Clearside Biomedical (NASDAQ:CLSD) reported that Health Canada approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME), marking a significant milestone in the company’s continued global expansion.

With this latest regulatory clearance, XIPERE is now approved in four global markets: the United States, Canada, Australia, and Singapore, with review currently underway in China. The approval not only validates Clearside’s innovative SCS injection platform but also continues to solidify the company’s presence in the international ophthalmology landscape.

XIPERE is a proprietary formulation of triamcinolone acetonide designed for suprachoroidal administration, specifically to treat macular edema associated with uveitis. It is administered using Clearside’s SCS Microinjector, a patented in-office device that enables targeted drug delivery to the back of the eye. XIPERE was the first therapy approved in the U.S. for suprachoroidal use and is commercially available through Bausch + Lomb, which holds exclusive rights in the U.S. and Canada.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CLSD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.